胆管细胞来源外泌体长链非编码RNA H19促进肝星状细胞活化与胆汁淤积性肝纤维化
该研究利用胆管结扎(BDL)和Mdr2敲除(Mdr2-/-)小鼠模型及人PSC/PBC肝样本,发现肝内H19水平与肝纤维化严重程度密切相关,H19缺陷可显著减轻小鼠肝纤维化;胆管细胞来源富含H19的外泌体被肝星状细胞快速优先摄取,促进其分化活化与基质形成,从而推动胆汁淤积性肝纤维化进展。
要点
- 肝内H19水平在小鼠模型及人PSC/PBC患者中均与肝纤维化严重程度密切相关。
- H19缺陷显著减轻BDL和Mdr2-/-小鼠的肝纤维化。
- 胆管细胞来源富含H19的外泌体被HSC优先摄取,促进HSC分化活化与纤维化。
核心结论
- 胆管细胞来源外泌体H19通过促进HSC分化和活化在胆汁淤积性肝纤维化进展中起关键作用,并可能作为胆管病的诊断生物标志物和治疗靶点。
研究设计与样本
- 研究采用BDL和Mdr2-/-小鼠模型,将野生型与H19maternalΔExon1/+(H19KO)小鼠行BDL,并构建Mdr2-/- H19maternalΔExon1/+(DKO)小鼠;使用培养的小鼠和人胆管细胞或小鼠血清来源外泌体进行体内移植和体外研究;采用荧光标记外泌体和流式细胞术监测肝细胞对外泌体的摄取;通过胶原凝胶收缩和溴脱氧尿苷实验检测外泌体H19对HSC活化和增殖的影响;对人PSC/PBC肝样本进行实时PCR、蛋白质印迹、组织学和免疫组化分析。
主要发现
- 肝内H19水平在小鼠模型及人PSC和PBC患者中均与肝纤维化严重程度密切相关。
- H19缺陷显著保护BDL和Mdr2-/-小鼠免于肝纤维化。
- 移植的胆管细胞来源富含H19外泌体被HSC及HSC来源成纤维细胞快速优先摄取,并在BDL-H19KO小鼠和DKO小鼠中促进肝纤维化。
- 富含H19外泌体增强培养的小鼠原代HSC转分化,并促进HSC来源成纤维细胞增殖和基质形成。
临床怎么用
- 原文结论认为胆管细胞来源外泌体H19可能作为胆管病的诊断生物标志物和治疗靶点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Activation of hepatic stellate cells (HSCs) represents the primary driving force to promote the progression of chronic cholestatic liver diseases. We previously reported that cholangiocyte-derived exosomal long noncoding RNA-H19 (lncRNA-H19) plays a critical role in promoting cholestatic liver injury. However, it remains unclear whether cholangiocyte-derived lncRNA-H19 regulates HSC activation, which is the major focus of this study. Both bile duct ligation (BDL) and Mdr2 knockout (Mdr2-/- ) mouse models were used. Wild-type and H19maternalΔExon1/+ (H19KO) mice were subjected to BDL. Mdr2-/- H19maternalΔExon1/+ (DKO) mice were generated. Exosomes isolated from cultured mouse and human cholangiocytes or mouse serum were used for in vivo transplantation and in vitro studies. Fluorescence-labeled exosomes and flow cytometry were used to monitor exosome uptake by hepatic cells. Collagen gel contraction and bromodeoxyuridine assays were used to determine the effect of exosomal-H19 on HSC activation and proliferation. Mouse and human primary sclerosing cholangitis (PSC)/primary biliary cholangitis (PBC) liver samples were analyzed by real-time PCR, western blot analysis, histology, and immunohistochemistry. The results demonstrated that hepatic H19 level was closely correlated with the severity of liver fibrosis in both mouse models and human patients with PSC and PBC. H19 deficiency significantly protected mice from liver fibrosis in BDL and Mdr2-/- mice. Transplanted cholangiocyte-derived H19-enriched exosomes were rapidly and preferentially taken up by HSCs and HSC-derived fibroblasts, and promoted liver fibrosis in BDL-H19KO mice and DKO mice. H19-enriched exosomes enhanced transdifferentiation of cultured mouse primary HSCs and promoted proliferation and matrix formation in HSC-derived fibroblasts. Conclusion: Cholangiocyte-derived exosomal H19 plays a critical role in the progression of cholestatic liver fibrosis by promoting HSC differentiation and activation and represents a potential diagnostic biomarker and therapeutic target for cholangiopathies.
引用
- Liu R, Li X, Zhu W, et al. Cholangiocyte-Derived Exosomal Long Noncoding RNA H19 Promotes Hepatic Stellate Cell Activation and Cholestatic Liver Fibrosis. Hepatology. 2019. PMID: 30985008. doi:10.1002/hep.30662
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。